Press Release

October 30, 2018

DSM informs market on the completion of the sale of Fibrant’s caprolactam business to Highsun

DSM anticipates receiving about €200 million in cash in various steps in 2018 and 2019.

print

Heerlen, NL, 30 Oct 2018 11:00 CET

Royal DSM, a global science-based company in Nutrition, Health and Sustainable Living, informs its stakeholders that Fibrant Holding BV has completed the sale of Fibrant BV and 60% of the shares of Fibrant China to the Highsun Holdings Group Ltd.  

Through the joint venture Chemicalnvest, DSM and CVC Capital Partners indirectly owned 35% and 65% respectively of the shares of Fibrant BV and in the same proportion 60% of the shares in Fibrant China. The transaction was announced on 17 May 2018. DSM anticipates receiving about €200 million in cash related to this transaction, which is expected to be received in various steps in 2018 and 2019.

DSM still owns 19% in AOC Aliancys (the composite resins joint venture with CVC) and 35% in AnQore (the acrylonitrile joint venture with CVC).

For more information
Lieke de Jong-Tops

Senior Communications Manager
+31 45 578 2420
media.contacts@dsm.com

Dave Huizing

Vice President Investor Relations
+31 45 578 2864
investor.relations@dsm.com

Lieke de Jong-Tops

Senior Communications Manager
+31 45 578 2420

Dave Huizing

Vice-President Investor Relations
+31 45 578 2864